TPWA
DYN icon

Twin Peaks Wealth Advisors’s Dyne Therapeutics DYN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14
Closed -$254 – 777
2026
Q1 		$254 Buy
+14
New +$241 ﹤0.01% 2140

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Twin Peaks Wealth Advisors's DYN Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 14 shares — an estimated $254 sold.

Twin Peaks Wealth Advisors first reported a position in DYN in Q1 2026 and held it in 1 quarter. The position peaked at $254 in Q1 2026. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 14 Dyne Therapeutics shares in Q2 2026, an estimated $254.
  • Twin Peaks Wealth Advisors first reported a position in Dyne Therapeutics in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Dyne Therapeutics position peaked at $254 in Q1 2026.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.